Melatonin in Healthy Aging and Longevity

Hardeland, Rüdiger

doi:10.1007/978-3-319-63001-4_10

Cited by 11 publications

(4 citation statements)

References 204 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the higher insulin levels in diabetic subjects, diabetes mellitus is accompanied by lower serum concentrations of melatonin in diabetic GotoKakizaki rats [8]. Furthermore, melatonin functions as an anti-aging [9], anti-inflammatory, antioxidant [10] as well as antihypertensive agent [11]. This review summarizes the therapeutic potentials of melatonin in the treatment of diabetes mellitus and its complications, based on findings of recent studies.…”

Section: Introductionmentioning

confidence: 99%

Melatonin: new insights on its therapeutic properties in diabetic complications

Pourhanifeh

Hosseinzadeh

Dehdashtian

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

Diabetes and diabetic complications are considered as leading causes of both morbidity and mortality in the world. Unfortunately, routine medical treatments used for affected patients possess undesirable side effects, including kidney and liver damages as well as gastrointestinal adverse reactions. Therefore, exploring the novel therapeutic strategies for diabetic patients is a crucial issue. It has been recently shown that melatonin, as main product of the pineal gland, despite its various pharmacological features including anticancer, anti-aging, antioxidant and antiinflammatory effects, exerts anti-diabetic properties through regulating various cellular mechanisms. The aim of the present review is to describe potential roles of melatonin in the treatment of diabetes and its complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Melatonin: new insights on its therapeutic properties in diabetic complications

Pourhanifeh

Hosseinzadeh

Dehdashtian

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…Previously, some authors [43] have shown that melatonin is a geroprotector. However, not all studies note the geroprotective properties of melatonin [44]. Nevertheless, it is shown that MT reduces the risk of developing oncological [43], cardiovascular [45], and neurodegenerative [46] diseases and, as a result, increases the duration of a healthy life [44].…”

Section: Discussionmentioning

confidence: 99%

“…However, not all studies note the geroprotective properties of melatonin [44]. Nevertheless, it is shown that MT reduces the risk of developing oncological [43], cardiovascular [45], and neurodegenerative [46] diseases and, as a result, increases the duration of a healthy life [44]. Until recently, a pharmacologically pure melatonin preparation was used in gerontological studies.…”

Section: Discussionmentioning

confidence: 99%

The Positive Association between Melatonin-Containing Food Consumption and Older Adult Life Satisfaction, Psychoemotional State, and Cognitive Function

Borisenkov,

Dorogina,

Popov

et al. 2024

Nutrients

View full text Add to dashboard Cite

The purpose of this study was to test the hypothesis that melatonin-containing food (FMT) consumption is associated with a better sleep schedule and cognitive and psychoemotional state in older adults. A cross-sectional study of 557 (79% females) older adults living in the community with a mean age of 68.9 ± 7.7, ranging from 50 to 90 years, was conducted. The study, conducted in May and September 2023 using a face-to-face interview, collected personal data and assessed FMT intake during the day (FMTday) and for dinner (FMTdinner), life satisfaction, positive and negative affect, depression severity, cognitive functions, and sleep characteristics. Multiple regression and logistic regression analysis, adjusted for co-factors, were used to assess the association between the studied indicators. Multiple regression analysis showed that older adults with higher FMT consumption are more satisfied with life (FMTdinner: β = 0.107; ∆R2 = 0.011; p = 0.020), have a lower level of depression (FMTday: β = −0.124; ∆R2 = 0.015; p = 0.003), and higher scores in positive affect (FMTday: β = 0.169; ∆R2 = 0.016; p = 0.007; FMTdinner: β = 0.136; ∆R2 = 0.019; p = 0.003). Logistic regression analysis showed that older adults with higher FMT consumption are less likely to have depression (FMTday: OR, 0.614; 95% CI, 0.436–0.864; p = 0.005; FMTdinner: OR, 0.671; 95% CI, 0.476–0.945; p = 0.023), and they perform better on logical thinking tests (FMTday: OR, 2.066; 95% CI, 1.131–2.204; p = 0.013; FMTdinner: OR, 1.887; 95% CI, 1.183–2.138; p = 0.033). A greater life satisfaction as well as a decrease in the cognitive impairment and psychoemotional state of older adults is associated with a higher consumption of melatonin-containing foods.

show abstract

“…[12] Additionally, melatonin functions as an anti-aging, potent anti-in ammatory, antioxidant, and antihypertensive agent. [13][14][15] The antioxidative effects of melatonin are attributed to its direct free radical scavenging properties as well as inducing the production of other antioxidant enzymes, including glutathione peroxidase (GPx), glutathione reductase (GR), catalase (CAT) and superoxide dismutase (SOD). [16-18] Additionally, melatonin has high pharmacological potency (a signi cant effect is observed from a 100 pM concentration) and a powerful antioxidant effect, suggesting that it may be effective in the treatment of diabetic nephropathy.…”

Section: Introductionmentioning

confidence: 99%

Investigating the effect of melatonin on serum changes of Adropin in patients with diabetic retinopathy, A randomized clinical trial

Javadzadeh,

ghodraty,

saeedi-maleki

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: This study aimed to determine the effect of oral melatonin on adropin serum levels in patients with diabetic retinopathy(DR) Methods and Design: This randomized, single-blind clinical trial involved 22 patients with DR who received additional treatment of 3 mg/day melatonin for three months (group A) and 22 age-matched patients with DR who got only the routine treatments (group B) A complete ophthalmic examination, including best corrected visual acuity (BCVA) (based on LogMAR) and slit lamp examination, was done. DR grading was based on Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines. serum levels of adropin, MDA, and hs-CRP were measured and repeated after 3 months. Descriptive statistics were used to describe demographic characteristics and inferential statistics (Mann Whitney U test, Spearman's rank correlation test) were used to describe the characteristics of the population, and the statistical significance level was set at P < 0.05. Results: Significant differences between the melatonin and control groups (both before and after the treatment) were seen with MDA (P = 0.005) and Adropin (P = 0.001), but there were no significant differences between the biochemical parameter levels. Also, there were no Significant correlations between the changes in Adropin level with biochemical parameter levels in three months. Conclusions: In conclusion, our study suggests that using melatonin alongside routine DR treatments may increase serum adropin levels and decrease the oxidative stress and inflammatory process of diabetes for this reason we may consider a therapeutic role for melatonin in treating diabetic retinopathy.

show abstract

Melatonin in Healthy Aging and Longevity

Cited by 11 publications

References 204 publications

Melatonin: new insights on its therapeutic properties in diabetic complications

Melatonin: new insights on its therapeutic properties in diabetic complications

The Positive Association between Melatonin-Containing Food Consumption and Older Adult Life Satisfaction, Psychoemotional State, and Cognitive Function

Investigating the effect of melatonin on serum changes of Adropin in patients with diabetic retinopathy, A randomized clinical trial

Contact Info

Product

Resources

About